<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01576731</url>
  </required_header>
  <id_info>
    <org_study_id>2011-003799-35</org_study_id>
    <nct_id>NCT01576731</nct_id>
  </id_info>
  <brief_title>Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir (RAL-PEP)</brief_title>
  <acronym>RAL-PEP</acronym>
  <official_title>Open Randomized Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      As a measure of secondary prophylaxis, and with the final objective of avoiding the
      infection, it has been suggested to use antiretroviral therapy. This is known as
      post-exposure prophylaxis (PEP).

      Although there are different recommendations, almost every guideline recommend using 3 drugs
      as PEP both in USA and Europe.

      Toxicity is one of the main limitations of PEP. Side effects during PEP are very usual, are
      attributed mainly to PI and are the main reasons for poor adherence or lost of follow-up.

      A current standard regimen is AZT+3TC (Combivir®) or tenofovir+emtricitabine (Truvada®) plus
      the PI lopinavir/r. Toxicity associated with this regimens are high (31-85% of cases),with a
      high tolerability, a integrase inhibitor (raltegravir)could be an adequate drug for PEP.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients dropping out before the 28 days of postexposure prophylaxis</measure>
    <time_frame>28 days</time_frame>
    <description>Proportion of patients droppping out before the 28 days of postexposure prophylaxis considering death, lost to folow-up and stopping or changing treatment for any reason</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Tenofovir + emtricitabine + lopinavir/r</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard postexposure prophylaxis combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tenofovir + Emtricitabine + Raltegravir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>new postexposure prophylaxis combination</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir, Emtricitabine, Lopinavir/r</intervention_name>
    <description>Combination drug</description>
    <arm_group_label>Tenofovir + emtricitabine + lopinavir/r</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir, Emtricitabine, Raltegravir</intervention_name>
    <description>Combination drug</description>
    <arm_group_label>Tenofovir + Emtricitabine + Raltegravir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Potentially sexual exposition to HIV

        Exclusion Criteria:

          -  Pregnancy

          -  Source case with antiretroviral resistances

          -  any treatment contraindicated with the drugs of study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Felipe Garcia, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Consultant senior</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clínic of Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2012</study_first_submitted>
  <study_first_submitted_qc>April 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2012</study_first_posted>
  <last_update_submitted>March 31, 2015</last_update_submitted>
  <last_update_submitted_qc>March 31, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>Felipe Garcia</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>HIV Infection</keyword>
  <keyword>Postexposure prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

